Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Merestinib in Healthy Subjects
NCT02370485Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of merestinib in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 120 hours and Area Under the Concentration Curve 0-infinity at 120 hours. Started Feb 2015; status: completed.
02
Drugs
merestinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02370485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370485.